SGMT Stock Overview
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Sagimet Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.92 |
| 52 Week High | US$20.71 |
| 52 Week Low | US$2.13 |
| Beta | 0 |
| 1 Month Change | -25.05% |
| 3 Month Change | -63.26% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -75.42% |
Recent News & Updates
Shareholder Returns
| SGMT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.3% | 0.4% | 1.0% |
| 1Y | n/a | 0.9% | 21.9% |
Return vs Industry: Insufficient data to determine how SGMT performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how SGMT performed against the US Market.
Price Volatility
| SGMT volatility | |
|---|---|
| SGMT Average Weekly Movement | 19.0% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SGMT's share price has been volatile over the past 3 months.
Volatility Over Time: SGMT's weekly volatility has decreased from 33% to 19% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 9 | Dave Happel | www.sagimet.com |
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company’s lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs.
Sagimet Biosciences Inc. Fundamentals Summary
| SGMT fundamental statistics | |
|---|---|
| Market cap | US$125.10m |
| Earnings (TTM) | -US$27.88m |
| Revenue (TTM) | US$2.00m |
62.6x
P/S Ratio-4.5x
P/E RatioIs SGMT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SGMT income statement (TTM) | |
|---|---|
| Revenue | US$2.00m |
| Cost of Revenue | US$0 |
| Gross Profit | US$2.00m |
| Other Expenses | US$29.88m |
| Earnings | -US$27.88m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.87 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,393.80% |
| Debt/Equity Ratio | 0% |
How did SGMT perform over the long term?
See historical performance and comparison